Astellas Pharma (4503): CSP2026: cost optimization strengthens earnings; pipeline key to growth

Research evidence excerpt

Astellas Pharma (4503): CSP2026: cost optimization strengthens earnings; pipeline key to growth

Accessible version

Astellas Pharma (4503)

CSP2026: cost optimization strengthens

earnings; pipeline key to growth

Maintain Rating: BUY | PO: 2,950 JPY | Price: 2,234 JPY

26 May 2026

Maintain Buy; cash flow focus, no earnings guidance Equity

After the market close on 26 May, Astellas held a briefing on its new Corporate Strategic

Plan (CSP). Under CSP 2026, the company aims to achieve record‑high revenue levels by Koichi Mamegano >>

Research Analyst

the mid‑2030s, driven by its pipeline. While the absence of explicit earnings guidance is BofAS Japan

somewhat disappointing, the plan’s emphasis on strengthening cash flow generation koichi.mamegano@bofa.com

over short‑term earnings is notable. Management outlined a target to increase Takefumi Kobayashi >>

cumulative cash flow over the next five years from ¥3.4tn under the previous plan to BofAS Japan

¥4.3tn. Even against a backdrop of declining earnings, the plan suggests an improvement takefumi.kobayashi@bofa.com

in underlying cash generation at the business level, and we do not view the lack of Ritsuo Watanabe >>

earnings visibility as a major concern. We maintain our Buy rating with a price objective BofAS Japan

(PO) of ¥2,950. ritsuo.watanabe@bofa.com

FY3/30 revenue trough; pipeline-driven recovery

Astellas targets a doubling of revenue from its key strategic brands, from ¥480bn in Stock Data

FY3/26 to FY3/31. However, total revenue is expected to bottom out in FY3/30 due to

the impact of the patent expiry of Xtandi (prostate cancer). Thereafter, management Price (Common / ADR) 2,234 JPY / 14.21 USD

aims to drive a pipeline‑led recovery, with pipeline sales potential estimated at Price Objective 2,950 JPY / 19.00 USD